NCT05518201 2024-04-17Evaluate the Safety and Immunogenicity of a 9-valent HPV Vaccine in Chinese Healthy Male Aged 9-45 Year-oldShanghai Bovax Biotechnology Co., Ltd.Phase 1 Completed90 enrolled